Related Experiment Video
Updated: Jan 30, 2026

Retinal Detachment Model in Rodents by Subretinal Injection of Sodium Hyaluronate
Published on: September 11, 2013
Oral Selumetinib Does Not Negatively Impact Photoreceptor Survival in Murine Experimental Retinal Detachment
Colleen M Cebulla1, Bongsu Kim1, Valerie George1
1Havener Eye Institute, Department of Ophthalmology and Visual Science, The Ohio State University Wexner Medical Center, Columbus, Ohio, United States.
Purpose:
Mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling is neuroprotective in some retinal damage models but its role in neuronal survival during retinal detachment (RD) is unclear. In addition, serous RDs are a prevalent side effect of MEK inhibitors (MEKi), blocking MAPK/ERK signaling for treatment of certain cancers. We tested the hypothesis that MEKi treatment in experimental RD would increase photoreceptor death.
Methods:
The MEKi selumetinib was delivered daily to C57BL/6 mice at a clinically relevant dose (10 mg/mL) starting 1 day prior to creating RD with subretinal hyaluronic acid injection. Photoreceptor TUNEL and outer nuclear layer (ONL) thickness were analyzed. Phospho-ERK1/2 (pERK) distribution, glial fibrillary acidic protein (GFAP) accumulation, and Iba-1 (microglia/macrophages) were evaluated with immunofluorescence.
Results:
pERK accumulated in the Müller glia in detached retinas, but this was effectively blocked by selumetinib. Selumetinib did not induce serous RDs at day 1 and did not increase TUNEL positive photoreceptors or further decrease ONL thickness compared to controls. Retinal gliosis was not altered, but selumetinib did block the increase in intraretinal microglia/macrophage Iba-1 fluorescence intensity and acquisition of amoeboid morphology.
Conclusions:
MAPK/ERK is neuroprotective in some retinal damage models; in RD, selumetinib blocked Müller pERK accumulation and changed the retinal microglia/macrophage phenotype but did not alter photoreceptor survival. This is consistent with the relatively good visual acuity seen in patients developing transient retinal detachments on MEK inhibitor therapy. Compensation by other neuroprotective pathways in the retina during retinal detachment may occur in the presence of MEK inhibition.
Insights
MEK inhibitors (MEKi) did not increase photoreceptor death in experimental retinal detachment (RD), despite blocking protective MAPK/ERK signaling. This suggests other pathways may compensate for MEKi effects during RD.
Area of Science:
- Ophthalmology
- Neuroscience
- Oncology
Background:
- Mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling offers neuroprotection in certain retinal damage models.
- The role of MAPK/ERK signaling in neuronal survival during retinal detachment (RD) remains unclear.
- Serous RDs are a common side effect of MEK inhibitors (MEKi), used in cancer therapy to block MAPK/ERK signaling.
Purpose of the Study:
- To investigate the hypothesis that MEK inhibitor (MEKi) treatment exacerbates photoreceptor death in experimental retinal detachment (RD).
Main Methods:
- Experimental retinal detachment (RD) was induced in C57BL/6 mice.
- Mice received daily doses of the MEKi selumetinib.
- Photoreceptor survival (TUNEL assay) and outer nuclear layer (ONL) thickness were analyzed.
- Immunofluorescence was used to assess phospho-ERK1/2 (pERK), glial fibrillary acidic protein (GFAP), and Iba-1.
Main Results:
- Selumetinib blocked pERK accumulation in Müller glia within detached retinas.
- No increase in serous RDs, photoreceptor death, or ONL thinning was observed in selumetinib-treated mice compared to controls.
- Selumetinib prevented the increase in intraretinal microglia/macrophage Iba-1 intensity and amoeboid morphology, while not altering retinal gliosis.
Conclusions:
- In experimental RD, selumetinib blocked Müller glia pERK accumulation and modulated microglia/macrophage responses but did not impair photoreceptor survival.
- These findings align with good visual acuity in patients experiencing transient RDs during MEK inhibitor therapy.
- Potential compensation by alternative neuroprotective pathways in the retina may occur during MEK inhibition in RD.
Related Concept Videos
Photoreceptors and Plant Responses to Light
Survival Curves
The Kaplan-Meier estimator is the most common method for constructing survival curves. This...
Survival Tree
Building a Survival Tree
Constructing a...
Impact of Groups on Groups
Photoreceptors and Visual Pathways
Negative Regulator Molecules

